The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice

Elena Quaglino; Cristina Mastini; Manuela Iezzi; Guido Forni; Piero Musiani; Leah N. Klapper; Britta Hardy; Federica Cavallo

doi:10.1016/j.vaccine.2005.01.086

The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice

Elena Quaglino, Cristina Mastini, Manuela Iezzi, Guido Forni, Piero Musiani, Leah N. Klapper, Britta Hardy, Federica Cavallo^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Over the course of 33 weeks from birth, the mammary glands of virgin female BALB/c mice transgenic for the transforming rat Her-2/neu oncogene progress from atypical hyperplasia to invasive carcinoma. By week 12, all their mammary glands display many foci of in situ carcinoma. DNA vaccination at weeks 12 and 14 through in vivo electroporation of a plasmid encoding for the extracellular and transmembrane domain of the protein product of rat Her-2/neu oncogene kept 33% of mice tumor-free until week 35, when the experiment ended. To improve its efficacy the vaccine was combined with a T cell stimulatory monoclonal antibody (BAT). When each plasmid electroporation was followed by intravenous administration of 10 μg of BAT monoclonal antibody at weeks 13 and 15, 55% of mice remained tumor free (p < 0.0001) and stronger T cell and antibody-mediated immune responses were elicited. These data suggest that costimulation by BAT monoclonal antibody enables DNA vaccination to establish an effective protection against incipient carcinomas.

Original language	English
Pages (from-to)	3280-3287
Number of pages	8
Journal	Vaccine
Volume	23
Issue number	25
DOIs	https://doi.org/10.1016/j.vaccine.2005.01.086
State	Published - 9 May 2005
Externally published	Yes

Keywords

BAT mAb
HER-2/neu
Immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.01.086

Cite this

@article{129483ccf5dd4d609d59e52f597838e0,

title = "The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice",

abstract = "Over the course of 33 weeks from birth, the mammary glands of virgin female BALB/c mice transgenic for the transforming rat Her-2/neu oncogene progress from atypical hyperplasia to invasive carcinoma. By week 12, all their mammary glands display many foci of in situ carcinoma. DNA vaccination at weeks 12 and 14 through in vivo electroporation of a plasmid encoding for the extracellular and transmembrane domain of the protein product of rat Her-2/neu oncogene kept 33% of mice tumor-free until week 35, when the experiment ended. To improve its efficacy the vaccine was combined with a T cell stimulatory monoclonal antibody (BAT). When each plasmid electroporation was followed by intravenous administration of 10 μg of BAT monoclonal antibody at weeks 13 and 15, 55% of mice remained tumor free (p < 0.0001) and stronger T cell and antibody-mediated immune responses were elicited. These data suggest that costimulation by BAT monoclonal antibody enables DNA vaccination to establish an effective protection against incipient carcinomas.",

keywords = "BAT mAb, HER-2/neu, Immunotherapy",

author = "Elena Quaglino and Cristina Mastini and Manuela Iezzi and Guido Forni and Piero Musiani and Klapper, {Leah N.} and Britta Hardy and Federica Cavallo",

note = "Funding Information: This work was funded by grants from the Italian Association for Cancer Research, the Italian Ministries for the University and Health, the University of Turin, Compagnia di San Paolo, Turin, and the Center of Excellence on Aging, University of Chieti, Italy. ",

year = "2005",

month = may,

day = "9",

doi = "10.1016/j.vaccine.2005.01.086",

language = "אנגלית",

volume = "23",

pages = "3280--3287",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "25",

}

TY - JOUR

T1 - The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice

AU - Quaglino, Elena

AU - Mastini, Cristina

AU - Iezzi, Manuela

AU - Forni, Guido

AU - Musiani, Piero

AU - Klapper, Leah N.

AU - Hardy, Britta

AU - Cavallo, Federica

N1 - Funding Information: This work was funded by grants from the Italian Association for Cancer Research, the Italian Ministries for the University and Health, the University of Turin, Compagnia di San Paolo, Turin, and the Center of Excellence on Aging, University of Chieti, Italy.

PY - 2005/5/9

Y1 - 2005/5/9

N2 - Over the course of 33 weeks from birth, the mammary glands of virgin female BALB/c mice transgenic for the transforming rat Her-2/neu oncogene progress from atypical hyperplasia to invasive carcinoma. By week 12, all their mammary glands display many foci of in situ carcinoma. DNA vaccination at weeks 12 and 14 through in vivo electroporation of a plasmid encoding for the extracellular and transmembrane domain of the protein product of rat Her-2/neu oncogene kept 33% of mice tumor-free until week 35, when the experiment ended. To improve its efficacy the vaccine was combined with a T cell stimulatory monoclonal antibody (BAT). When each plasmid electroporation was followed by intravenous administration of 10 μg of BAT monoclonal antibody at weeks 13 and 15, 55% of mice remained tumor free (p < 0.0001) and stronger T cell and antibody-mediated immune responses were elicited. These data suggest that costimulation by BAT monoclonal antibody enables DNA vaccination to establish an effective protection against incipient carcinomas.

AB - Over the course of 33 weeks from birth, the mammary glands of virgin female BALB/c mice transgenic for the transforming rat Her-2/neu oncogene progress from atypical hyperplasia to invasive carcinoma. By week 12, all their mammary glands display many foci of in situ carcinoma. DNA vaccination at weeks 12 and 14 through in vivo electroporation of a plasmid encoding for the extracellular and transmembrane domain of the protein product of rat Her-2/neu oncogene kept 33% of mice tumor-free until week 35, when the experiment ended. To improve its efficacy the vaccine was combined with a T cell stimulatory monoclonal antibody (BAT). When each plasmid electroporation was followed by intravenous administration of 10 μg of BAT monoclonal antibody at weeks 13 and 15, 55% of mice remained tumor free (p < 0.0001) and stronger T cell and antibody-mediated immune responses were elicited. These data suggest that costimulation by BAT monoclonal antibody enables DNA vaccination to establish an effective protection against incipient carcinomas.

KW - BAT mAb

KW - HER-2/neu

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=17144388293&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.01.086

DO - 10.1016/j.vaccine.2005.01.086

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 15837233

AN - SCOPUS:17144388293

SN - 0264-410X

VL - 23

SP - 3280

EP - 3287

JO - Vaccine

JF - Vaccine

IS - 25

ER -

The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this